CX3CL1 and Alzheimer disease: In AD pathology, evidence from complementary techniques revealed that fractalkine signaling is detrimental during amyloid pathology, yet beneficial in Tau pathology (Lee et al., 2010; Chen et al., 2016; Bemiller et al., 2018).